KIF5B and non-small cell lung carcinoma: Interestingly, poor clinical outcomes have also been reported in patients with NSCLC harboring KIF5B-RET rearrangement treated with other above mentioned MKIs in several phase II trials [43,49,61,62], compared to patients with non-KIF5B-RET NSCLC.